Helio Health
Max Gallant has extensive experience in the biotechnology industry. Max began their career at MorNuCo, Inc. in 2016, where they held various roles including Flex-Lab Director, Director of Special Projects, and VP of Research. In 2017, they moved to Helio Genomics, where they served as the Director of Diagnostics before advancing to the role of Director of R&D, NGS.
Max Gallant holds a Bachelor's degree in Biochemistry from Université Laval. Max then pursued a Master's degree and a Doctor of Philosophy (PhD) in Immunology from Université de Sherbrooke.
This person is not in any offices
Helio Health
Helio Health is an AI-driven healthcare company focused on commercializing early cancer detection tests from a simple blood draw. The company’s mission is to simplify cancer screening so lives can be saved by detecting cancer earlier. With Helio’s AI-driven technology, both physicians and their patients gain powerful insights from accurate,accessible, and convenient blood tests. Helio’s development program is focused on liver, colon, breast and lung cancer. Helio Health is headquartered in Irvine, CA, with R&D, GMP and CLIA facilities in Irvine, CA and West Lafayette, IN.